Fig. 5
From: Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
Neutralization ability and in vivo therapeutic assays of SARS-CoV-2 BA.5 of RBD-hAb-B22. A Neutralizing RBD-hAb-B22 antibody inhibits SARS-CoV-2 BA.5 variant according to PRNT assay. The PRNT50 value was calculated with Prism software (data are presented as mean ± SD). B Schematic of the design for neutralizing RBD-hAb-B22 antibody against SARS-CoV-2 BA.5. One day after intranasal (i.n.) infection of SARS-CoV-2 BA.5, the K18-hACE2 mice were given a single intraperitoneal injection of either RBD-hAb-B22 3 mg/kg (n = 4), RBD-hAb-B22 6 mg/kg (n = 4), or normal human IgG control 6 mg/kg (n = 4). On day 3 after virus inoculation, lung samples were collected for analysis. C The viral loads in the lungs of treated mice were determined as median tissue culture infectious dose per mL (TCID50/mL). p values were calculated by two-tailed Student’s t test. *p < 0.05 ***p < 0.001